

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
INTRODUCTION	1		
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	6
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	6
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6-7
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	7
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	5-6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	5-6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	7
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	7-8
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	7-8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	-
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	-
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	7-8
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	7-8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	_
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	-
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS	1		
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	8
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8
Study characteristics	17	Cite each included study and present its characteristics.	8
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	11
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	8
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	9-10
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	9-10
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	9-10
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	-
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	11-14
	23b	Discuss any limitations of the evidence included in the review.	15
	23c	Discuss any limitations of the review processes used.	15
	23d	Discuss implications of the results for practice, policy, and future research.	16
OTHER INFORMA	TION		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	5
protocor	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	5
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	5
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	17
Competing interests	26	Declare any competing interests of review authors.	17
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	17

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

PubMed: 559 results

("vasopressor*" OR epinephrine[MeSH Terms] OR norepinephrine[MeSH Terms] OR phenylephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR Dopamine[MeSH Terms] OR angiotensins[MeSH Terms]) AND (covid-19) Filters: English

Scopus: 401 results

TITLE-

ABS ("vasopressor*" OR "epinephrine" OR "norepinephrine" OR "phenylephrine" OR "vasopressin*" OR "dopamine" OR "angiotensin") AND TITLE-ABS-KEY ("COVID-19") AND TITLE-ABS-KEY ("critically ill" OR icu OR "intensive care") AND (EXCLUDE (SRCTYPE, "k") OR EXCLUDE (SRCTYPE, "p")) AND (EXCLUDE (DOCTYPE, "re") OR EXCLUDE (DOCTYPE, "le") OR EXCLUDE (DOCTYPE, "sh") OR EXCLUDE (DOCTYPE, "cp") OR EXCLUDE (DOCTYPE, "ch") OR EXCLUDE (DOCTYPE, "tb")) AND (EXCLUDE (LANGUAGE, "French") OR EXCLUDE (LANGUAGE, "Russian") OR EXCLUDE (LANGUAGE, "Persian") OR EXCLUDE (LANGUAGE, "Persian") OR EXCLUDE (LANGUAGE, "Portuguese") OR EXCLUDE (LANGUAGE, "German") OR EXCLUDE (LANGUAGE, "Hungarian"))

Clinicaltrials.gov: 15 results

Completed Studies | (vasopressor OR epinephrine OR norepinephrine OR phenylephrine OR vasopressin OR Dopamine OR angiotensin) AND (covid-19)

1 Al Ashar	_	A	В	С	D	E	F	G	Н	1	J	K	L	M	N	0	ì
13 18 Imail In-haspital mortality NA NA NA NA NA NA NA N		Ά	Author	Mortality Definition	AKI Definition												
13 18 Imail In-haspital mortality NA NA NA NA NA NA NA N	2	1	lonescu	In-hospital mortality	NA												
13 18 Imail In-haspital mortality NA NA NA NA NA NA NA N	3	2	Pelayo	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines												
13 18 Imail In-haspital mortality NA NA NA NA NA NA NA N	4	3	Lowe	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines												
13 18 Imail In-haspital mortality NA NA NA NA NA NA NA N	5	4	Hansrivijit	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines												
19 18 Imail In-hospital mortality NA NA NA NA NA NA NA N	6	5	Mesquida	NA	NA												
19 18 bmail bi-hospital mortality NA NA NA NA NA NA NA N	7	6	Ghosn	In-hospital mortality	Data only for patients with Stage 2 and Stage 3 Kidney Disease: Improving Global Outcomes (KDKGO) guidelines												
19 18 Imail In-hospital mortality NA NA NA NA NA NA NA N	8	7	Farooqui	30-day mortality	NA]
19 18 bmail bi-hospital mortality NA NA NA NA NA NA NA N	9	8	de Menezes Neves	30-day mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines]]
19 18 bmail bi-hospital mortality NA NA NA NA NA NA NA N	10	9	Bernardo	NA	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines]
19 18 bmail In-hospital mortality NA NA NA NA NA NA NA N	11	10	Hardenberg	In-hospital mortality	Data only for patients with Stage 3 Kidney Disease: Improving Global Outcomes (KDKGO) guidelines]
19 18 Immail In-hospital mortality NA NA NA NA NA NA NA N	12	11	Geri	28-day mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines]]
19 18 bmail In-hospital mortality NA NA NA NA NA NA NA N	13	12	Namendys-Silva	In-hospital mortality	NA]]
19 18 Immail In-hospital mortality NA NA NA NA NA NA NA N	14	13		,	NA]]
19 18 Immail In-hospital mortality NA NA NA NA NA NA NA N	15	14	Nabors	In-hospital mortality	NA]]
19 18 Email In-hospital mortality NA NA NA NA NA NA NA N	16	15		, ,	NA]]
19 18 Immail In-hospital mortality NA NA NA NA NA NA NA N	17	16	Nasrulah	In-hospital mortality	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	18	17	Sjostorm	90-day mortality	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	19	18	bmail	In-hospital mortality	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	20	19	Osofu-Barko	NA	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	21	20	Ramkumar	NA	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	22	21	ACCCOS	30-day mortality	NA]]
25 24 Chand 30-day mortality Kidney Disease: Improving Global Outcomes (KDIGO) guidelines	23	22	Mamen	NA	NA]]
26 25 Bazzera In-hospital mortality Kidney Disease: Improving Global Outcomes (KDKGO) guidelines 27 0 Gundogan 90-day mortality Kidney Disease: Improving Global Outcomes (KDKGO) guidelines 28 27 Dang In-hospital mortality NA 29 Gadhiya In-hospital mortality NA 10 Brandao Neto In-hospital mortality NA 11 30 Brandao Neto In-hospital mortality NA 12 2 Tangrillo one-week after angiotensin administration NA 13 31 Loisman In-hospital mortality NA 14 33 Loisman In-hospital mortality NA 15 In-hospital mortality NA 16 In-hospital mortality NA 17 In-hospital mortality NA 18 In-hospital mortality NA 19 In-hospital mortality NA 19 In-hospital mortality NA 10 In-hospital mortality NA 11 In-hospital mortality NA 12 In-hospital mortality NA 13 In-hospital mortality NA 14 In-hospital mortality NA 15 In-hospital mortality NA 16 In-hospital mortality NA 17 In-hospital mortality NA 18 In-hospital mortality NA 19 In-hospital mortality NA 10 In-hospital mortality NA 10 In-hospital mortality NA 11 In-hospital mortality NA 12 In-hospital mortality NA 13 In-hospital mortality NA 14 In-hospital mortality NA 15 In-hospital mortality NA 16 In-hospital mortality NA 17 In-hospital mortality NA	24	23	Andrade	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDKGO) guidelines]]
32 31 Burrell KU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 37 38 39 September 1997 September 200 Se	25	24	Chand	30-day mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines												
32 31 Burrell KU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 37 38 39 September 1997 September 200 Se	26	25	Bezzera	In-hospital mortality													
32 31 Burrell KU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 37 38 39 September 1997 September 200 Se	27	26	Gundogan	90-day mortality]]
32 31 Burrell KU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 37 38 39 September 1997 September 200 Se	28	27	Dang	In-hospital mortality	NA][]
32 31 Burrell KU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 37 38 39 September 1997 September 200 Se	29	28	Estella	6-week mortality	NA												
32 31 Burrell KCU mortality NA 33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KCU mortality and in-hospital mortality NA 36 STATE OF THE	30	29	Gadhiya	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines]]
33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 Society of the second of the	31	30	Brandao Neto	In-hospital mortality	NA]]
33 32 Zangrillo one-week after angiotensin administration NA 34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 Society of the second of the	32	31	Burrell	ICU mortality	NA												
34 33 Leisman In-hospital mortality NA 35 34 Neto KU mortality and in-hospital mortality NA 36 Substituting the substitution of the substituting the substitution of the s	33	32	Zangrillo	one-week after angiotensin administration	NA												
	34	33		•	NA												
	35	34			NA												
	36																
	37																
C1_Definitions C2_Angiotensin data C3_MINORS 🕀	38																Ⅎ⅀
	4	(→ C1_D	C2_ Angiotensin data	C3_MINORS	: [4										·]

4	A	В	C	D	E	F	G	Н	1			
1			М	ortality			Adverse events (EVENTS/Patients)					
2	Author	Comment	Vasopress	Vasopressors Placebo-No vasopressors		lo vasopressors	Type of event	Intervention (Events/N of patients)	Placebo-No vasopressors (Events/N of patients)			
3			Deaths	N of patients	Deaths	N of patients						
4	Osofu-Barko	-	4	10		NA	-	-	-			
4 5 6	Leisman		4	10	10	19	Thrombotic events	0/10	3/19			
6	Leisillali	-	4	10	10	13	Secondary infection	3/10	7/19			
7		ICU mortality	33	65	24	67						
8	Neto	In-hospital mortality	35	65	27	67	AKI	50/65	44/64			
9												
10												
4	C1_Definit	ions C2_Angiotensin	data C3_MINORS	①			: 1					

N	J	K	L	М	N	0	P	Q					
1	-	or free days Median (IQR)		r free days Median (IQR)		Baseline hemodynamic profile Mean ± SD / Median (IQR)							
	Intervention	Placebo-No vasopressors	bo-No Intervention Placebo-No		HR (bpm)	MAP (mmHg)	Urinary output (ml/hr)	Lactate (mmol/L)					
3					Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors					
4	-	-	-	-	1	Mean: 75	Mean: 10	-					
5 6	2.8 ± 2.49	3.9 ± 2.5	0.3 ± 0.7	0.1 ± 0.5	-	69.2 (60-81)/83.2 (68-95)	-	-					
7 8	-	-	0 (0-15)	1 (0-15)	102 (81-118)/98 (86-102)	80 (69-94)/73 (63-89)	-	1.7 (1.4-2.2)/1.9 (1.2-2.5)					
9													
10	· (C1_Definitions	C2_Angiotens	sin data C3_M	iinors +		: •						

Q	R	S	T	U	v
			uscitation hemodynamic	•	
		M	ean ± SD / Median (IQR)	
Lactate (mmol/L)	Timepoints	HR (bpm)	MAP (mmHg)	Urinary output (ml/hr)	Lactate (mmol/L)
Vasopressors/No		Vasopressors/No	Vasopressors/No	Vasopressors/No	Vasopressors/No
vasopressors		vasopressors	vasopressors	vasopressors	vasopressors
-	6 hours after angiotensin administration		Mean: 85	Mean: 45	
-	6 hours after angiotensin administration	-	80 (NA) / NA	-	-
	6 hours after angiotensin administration	95 (77-104)/94 (81-111)	76 (65-87)/79 (69-86)		1.6 (1.2-2.4)/1.8 (1.2-2.4)
7 (1.4-2.2)/1.9 (1.2-2.5)	12 hours after angiotensin administration	79)72-81)/70 (69-87)	79 (72-81)/70 (69-87)	-	1.4 (1.2-2.1)/1.5 (1.3-2.1)
C2_Angiotensin data	C3_MINORS +		: 4		

4	A	В	С	D	E	F	G	Н	I	1	K	L	M	
1		Study	ACCOS	Andrade	Auld	Bernardo	Bezzera	Brandao Neto	Burrell	Chand	Dang	e Menezes Nev	Estella	
2		1	2	2	1	2	2	2	2	1	2	2		2
3		2	1	2	2	2	2	2	2	2	2	2		Ш
4		3	2	0	0	0	0	2	2	0	0	0		2
5		4	2	2	1	2	2	2	2	2	2	2		2
6		5	0	0	0	0	0	0	0	0	0	0	(0
7		6	2	2	1	2	2	2	2	2	2	2		2
8	Question/Parameter	7	2	2	2	2	2	2	2	2	2	2		2
9		8	0	0	0	0	0	0	0	0	0	0	(o
10						Additi	onal criteria fo	r comparative	studies					
11		9	2	2	2	2	2	2	2	2	2	2		2
12		10	2	2	2	2	2	2	2	2	2	2		2
13		11	0	0	0	0	0	0	0	0		0	(
14		12	2	2	2	1	2	2	2	2	2	2		2
15		Total	17	16	13	15	16	18	18	15	16	16	17	/
16														
17														$\ \ $
18														$\ \ $
19														$\ \ $
20														
21														
														$\ \ $
22 23 24 25														$\ \ $
24														
25														┛
-	C1_Defin	nitions C2_A	ngiotensin data C3_MI	NORS (+)			- 1	1	1				Þ	

4	A	В	N	0	P	Q	R	S	T	U	V	W	Х	Y
1		Study	Farooqui	Gadhiya	Geri	Ghosn	Hansrivijit	Hardenberg	Ionescu	Ismail	Leisman	Lowe	Nabors	Nasrulah
2		1	1	2	2	2	2	2		2	2 2	. 2	2	2
3		2	2	2	2	2	2	2		2	2 2	. 2	2	2
4		3	0	0	0	0	0	0	() (0	0	0	0
5		4	2	2	2	2	2	2		2	2	1	1	2
6		5	0	0	0	0	0	0	() (0	0	0	0
7		6	2	2	2	2	2	2		2	2 2	. 2	2	2
8	Question/Parameter	7	2	2	2	2	2	2		2	2 2	. 2	2	2
9		8	0	0	0	0	0	0	() (0	0	0	0
10														
11		9	2	2	2	2	2	2	7	2 2	2 2	. 2	2	2
12		10	2	2	2	2	2	2	7	2 7	2 2	. 2	2	2
13		11	. 0	0	0	0	0	0	() () 2	. 0	0	0
14		12	. 2	2	2	2	2	2		2	2 2	. 2	2	2
15		Total	15	16	16	16	16	16	16	5 16	18	15	15	16
16														
17														
18														
19 20														
20														
21 22														
23 24 25														
24														
25														
4	C1_Defi	nitions C2_	Angiotensin data	a C3_MING	ORS +				: [•				

4	A	В	Z	AA	AB	AC	AD	AE	AF	AG
1		Study	Neto	Osofu-Barko	Pelayo	Ramkumar	Salacup	Namendys-Silv	Sjostorm	Mammen
2		1	2	2	2	2	2	2	2	2
3		2	2	2	2	2	2	2	2	2
4		3	2	0	0	2	0	0	2	0
5		4	2	1	1	2	2	2	2	2
6		5	0	0	0	0	0	0	0	0
7		6	2	2	2	2	2	2	2	2
8	Question/Parameter	7	2	2	2	2	2	2	2	2
9		8	0	0	0	0	0	0	0	0
8 9 10 11										
		9	2	NA	2	2	2	2	2	2
12 13		10	2	NA	2	2	2	2	2	2
13		11	2	NA	0	0	0	0	0	0
14		12	2	NA	2	2	2	2	2	2
15		Total	20	9	15	18	16	16	18	16
16										
17										
18										
19										
20										
21										
22										
23										
23 24										
25										
-	C1_Defi	nitions C2_A	Angiotensin dat	a C3_MIN	ORS +				: •	



